Skip to main content
Fig. 3 | EJNMMI Research

Fig. 3

From: Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers

Fig. 3

Nano-SPECT/MRI imaging with 177Lu-CHX-A″ DTPA-labelled hu3S193 wild type (a, d) and I253A/H310A mutant (b, e) and huA33 wild type antibody (c, f) at day 2 post injection in A431 tumour-bearing mice. Representative whole body surface-rendered MRI images (ac) and maximum intensity projection SPECT image (df) are shown for each antibody. The T1 weighted MRI images clearly show the tumour (grey solid mass) surface of the lower abdomen, corresponding to the specific uptake of 177Lu-CHX-A″ DTPA-labelled hu3S193 wild type and I253A/H310A in tumours expressing Ley. Specific uptake of both hu3S193 wild type and hu3S193 I253A/H310A was demonstrated by the absence of huA33 uptake in the A33 antigen-negative A431 tumours

Back to article page